This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fridman, J. S. Articles by Lowe, S. W. Search for Related Content PubMed PubMed Citation Articles by Fridman, J. S. Articles by Lowe, S. W.

Tumor Promotion by Mdm2 Splice Variants Unable to Bind p53¹

Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 [J. S. F., M. T. H., E. d. S., S. W. L.], and Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [E. H., C. C-C.]

The Mdm2 oncoprotein physically associates with p53 and antagonizes its tumor suppressor functions. Previous studies indicate that some tumors express alternatively or aberrantly spliced Mdm2 variants that are unable to bind p53, but whether these actively contribute to carcinogenesis or are a byproduct of cancer progression has been unclear. In this study, we examined the ability of full-length Mdm2 and several tumor-derived splice variants to modulate tumor development in Eµ-myc transgenic mice. We report that several tumor-derived Mdm2 splice variants promote tumorigenesis in a manner that is comparable with full-length Mdm2. Our results imply that the current paradigm for understanding Mdm2 action during oncogenesis is incomplete, and its splice variants contribute to human cancer.

This article has been cited by other articles:

				E. L. Volk, L. Fan, K. Schuster, J. E. Rehg, and L. C. Harris The MDM2-A Splice Variant of MDM2 Alters Transformation In vitro and the Tumor Spectrum in Both Arf- and p53-Null Models of Tumorigenesis Mol. Cancer Res., June 1, 2009; 7(6): 863 - 869. [Abstract] [Full Text] [PDF]

				E. L. Volk, K. Schuster, K. M. Nemeth, L. Fan, and L. C. Harris MDM2-A, a common Mdm2 splice variant, causes perinatal lethality, reduced longevity and enhanced senescence Dis. Model. Mech., January 1, 2009; 2(1-2): 47 - 55. [Abstract] [Full Text] [PDF]

				J. S. Fridman, E. Caulder, M. Hansbury, X. Liu, G. Yang, Q. Wang, Y. Lo, B.-B. Zhou, M. Pan, S. M. Thomas, et al. Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1892 - 1902. [Abstract] [Full Text] [PDF]

				J.-Y. Yang, C. S. Zong, W. Xia, Y. Wei, M. Ali-Seyed, Z. Li, K. Broglio, D. A. Berry, and M.-C. Hung MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation. Mol. Cell. Biol., October 1, 2006; 26(19): 7269 - 7282. [Abstract] [Full Text] [PDF]

				C. S. Dias, Y. Liu, A. Yau, L. Westrick, and S. C. Evans Regulation of hdm2 by Stress-Induced hdm2alt1 in Tumor and Nontumorigenic Cell Lines Correlating with p53 Stability Cancer Res., October 1, 2006; 66(19): 9467 - 9473. [Abstract] [Full Text] [PDF]

				Y.-C. Wang, R.-K. Lin, Y.-H. Tan, J.-T. Chen, C.-Y. Chen, and Y.-C. Wang Wild-Type p53 Overexpression and Its Correlation With MDM2 and p14ARF Alterations: An Alternative Pathway to Non-Small-Cell Lung Cancer J. Clin. Oncol., January 1, 2005; 23(1): 154 - 164. [Abstract] [Full Text] [PDF]

				F. Bartel, L. C. Harris, P. Wurl, and H. Taubert MDM2 and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides Mol. Cancer Res., January 1, 2004; 2(1): 29 - 35. [Abstract] [Full Text] [PDF]

				S. P. Deb Cell Cycle Regulatory Functions of the Human Oncoprotein MDM2 Mol. Cancer Res., December 1, 2003; 1(14): 1009 - 1016. [Abstract] [Full Text] [PDF]